SCHEMBL970450

SCHEMBL970450

[CH2]Oc1ccc(CC)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.45
CYP2C19 P33261 1/20 0.45
TP53 P04637 1/20 0.43
ALDH1A1 P00352 2/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
TAAR1 Q96RJ0 1/20 0.42
RXRA P19793 1/20 0.41
RXRB P28702 1/20 0.41
CYP2A6 P11509 2/20 0.41
LPL P06858 1/20 0.41
LIPG Q9Y5X9 1/20 0.41
CYP1A2 P05177 1/20 0.39
TDP1 Q9NUW8 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
RAB9A P51151 1/20 0.39
SOD1 P00441 1/20 0.39
CA2 P00918 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2096437 0.80 THRB (0.53) ALDH1A1LMNATAAR1LPLLIPG
SCHEMBL8925998 0.78 SMN1; SMN2 (0.48) SMN1; SMN2CYP2C19TP53ALDH1A1LMNA
SCHEMBL475215 0.78 SMN1; SMN2 (0.48) SMN1; SMN2CYP2C19TP53ALDH1A1LMNA
SCHEMBL11725689 0.78 TAAR1 (0.52) SMN1; SMN2CYP2C19TP53ALDH1A1LMNA
SCHEMBL1047372 0.77 THRB (0.50) SMN1; SMN2TP53ALDH1A1LMNAMAPT
Ethylene SCHEMBL27468236 0.76 TP53 (0.59) SMN1; SMN2TP53ALDH1A1LMNATAAR1
SCHEMBL36295 0.76 TP53 (0.67) SMN1; SMN2TP53ALDH1A1LMNATAAR1
SCHEMBL30878 0.76 CA12 (0.61) SMN1; SMN2TP53ALDH1A1LMNAMAPT
SCHEMBL3138590 0.75 SMN1; SMN2 (0.48) SMN1; SMN2CYP2C19TP53ALDH1A1LMNA
SCHEMBL11504608 0.74 SMN1; SMN2 (0.50) SMN1; SMN2CYP2C19TP53ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110009463-A1 GERANYLGERANYL TRANSFERASE INHIBITORS AND METHODS OF MAKING AND USING THE SAME NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2011-01-13 US claimed
WO-2009051772-A1 GERANYLGERANYL TRANSFERASE INHIBITORS AND METHODS OF MAKING AND USING THE SAME DUKE UNIVERSITY (US) 2009-04-23 WO claimed
US-4707161-A Lightfastness of dyeings obtained with acid dyes or metal complex dyes on polyamides: treatment with copper hydroxamates BASF AKTIENGESELLSCHAFT (DE) 1987-11-17 US claimed
US-4562204-A ANTITUMOR, ANTILEUKEMIA AGENT ONO PHARMACEUTICAL CO., LTD. (JP) 1985-12-31 US claimed
EP-0097023-A2 Prostaglandin D derivatives, process for their preparation and compositions containing them ONO PHARMACEUTICAL CO., LTD. (JP) 1983-12-28 EP claimed
CN-111315828-B Composition, cured product, optical filter, and method for producing cured product 株式会社艾迪科 2023-09-29 CN disclosed
CN-112154167-B Composition, cured product, optical filter, and method for producing cured product 株式会社艾迪科 2023-08-22 CN disclosed
CN-107918247-B Colored curable resin composition 住友化学株式会社 2022-03-18 CN disclosed
CN-106019840-B Colored curable resin composition 东友精细化工有限公司 2021-01-29 CN disclosed
CN-112154167-A Composition, cured product, optical filter, and method for producing cured product 株式会社艾迪科 2020-12-29 CN disclosed
CN-111315828-A Composition, cured product, optical filter, and method for producing cured product 株式会社艾迪科 2020-06-19 CN disclosed
EP-3658112-A1 ACTIVE SUBSTANCE COMBINATIONS OF N-(4-AMINO-2-METHYLQUINOLINE-6-YL)-2-((4-ETHYLPHENOXY)METHYL) AND ONE OR MORE COSMETICALLY OR DERMATOLOGICALLY ACCEPTABLE PRESERVATIVES AND/OR PRESERVATIVE AUXILIARIES Beiersdorf AG (DE) 2020-06-03 EP disclosed
US-4367237-A THIOPGI-1 DERIVATIVES; OXYTOCICS; PREFERENTIAL ONO PHARMACEUTICAL CO., LTD. (JP) 1983-01-04 US disclosed
US-4351846-A 3-Hydroxy and 3-oxo-prostaglandin analogues ONO PHARMACEUTICAL CO., LTD. (JP) 1982-09-28 US disclosed
EP-0044711-A1 9,11-Methano-13-aza-11a-carbathrombanoic acid analogues and pharmaceutical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 1982-01-27 EP disclosed
EP-0017132-B1 DYESTUFFS, THEIR PREPARATION AND UTILISATION BASF Aktiengesellschaft (DE) 1981-10-14 EP disclosed
US-4284581-A LITHIUM 1,1'-BINAPHTHYL-2,2'-DIOXYALUMINUM HYDRIDE, REDUCING AGENTS ONO PHARMACEUTICAL CO., LTD. (JP) 1981-08-18 US disclosed
EP-0017132-A1 Dyestuffs, their preparation and utilisation BASF Aktiengesellschaft (DE) 1980-10-15 EP disclosed
US-4031082-A Process for preparing 3-acycloxymethyl-2-cephem compounds ELI LILLY AND COMPANY (US) 1977-06-21 US disclosed
US-4029651-A ESTERIFICATION ELI LILLY AND COMPANY (US) 1977-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009463-A1 GERANYLGERANYL TRANSFERASE INHIBITORS AND METHODS OF MAKING AND USING THE SAME FNTA, GGPS1, PTAR1 SMN1; SMN2 3969/4885CYP2C19 3340/4885TP53 2393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.